In 2006, Novartis dedicated US$755 million in company citizenship initiatives throughout the world, specifically concentrating on improving upon entry to medicines during the acquiring earth by its Entry to Medication assignments, which includes donations of medicines to sufferers affected by leprosy, tuberculosis, and malaria; Glivec individual ai